Table 1.
Enrolled patients
| Metastases | Gliomas | ||
|---|---|---|---|
| Sex | male | 32 (61.0 %) | 62 (59.1 %) |
| female | 21 (39.0 %) | 43 (40.9 %) | |
| Age (years) | Mean | 61.0. | 53.3 |
| Median | 63.0 | 53.7 | |
| Min | 24.2 | 16.0 | |
| Max | 89.4 | 84.3 | |
| Type of primary cancer/WHO-grade | lung cancer | 17 (30.0 %) | |
| breast cancer | 12 (21.0 %) | ||
| melanoma | 5 (9.0 %), | ||
| colon | 4 (7.0 %) | ||
| renal cancer | 4 (7.0 %) | ||
| others | 14 (26.0 %) | ||
| WHO I | - | 3 (2.7 %) | |
| WHOII | - | 17 (15.2 %) | |
| WHO III | - | 22 (19.6 %) | |
| WHO IV | - | 70 (62.5 %) | |
| Number | 1 | 32 (57.0 %) | 103 (100 %) |
| 2 | 10 (18.0 %) | ||
| 3 | 6 (11.0 %) | ||
| >3 | 8 (14.0 %) | ||
| location of tumor | frontodorsal/SMA | 27.0 % | 32.0 % |
| precentral gyrus | 37.0 % | 16.0 % | |
| postcentral gyrus | 14.0 % | 18.0 % | |
| CST | 22.0 % | 34.0 % | |
| preoperative status | paresis | 32 (57.0 %) | 35 (31.3 %) |
| seizures | 17 (30.0 %) | 24 (21.4 %) | |
| dizziness | 5 (9.0 %) | - | |
| incidental | 2 (4 %) | - | |
| hemihypesthesia | - | 19 (17.0 %) | |
| MEP changes | Intraoperative stable posthoc analysis >50 % amplitude loss | 29 (54.7 %) | 73 (65.2 %) |
| none (stable) | 32 (60.0 %) | 85 (80.1 %) | |
| reversible | 7 (13.0 %) | 9 (8.6 %) | |
| irreversible | 14 (27.0 %) | 11 (10.3 %) | |
| >80 % amplitude loss | |||
| none (stable) | 30 (56.6 %) | 24 (22.9 %) | |
| reversible | 20 (37.7 %) | 70 (66.7) | |
| irreversible | 3 (5.7 %) | 11 (10.3 %) | |
| surgery-related deficits | temporary | 5 (9.4 %) | 19 (18.1 %) |
| permanent | 7 (12.5 %) | 14 (12.5 %) | |
| Follow-up (months) | Mean ± SD | 2.9 ± 4.5 | 9.7 ± 10.5 |
| Median | 0.7 months | 6.1 | |
| Min | 0.1 | 0.5 | |
| Max | 20.1 | 40.6 | |
Overview of all enrolled patients including primary tumor, MEP changes intraoperatively, and surgery-related deficits